

Table E1. Results of Regression Analysis

Measure/Threshold/ No. in Sample	Univariate Cox Model Hazard Ratio/ <i>P</i> Value		Survival Proportions (mo)*				<i>P</i> Value	
	Conventional	CE T1W	Method/Threshold/ No. in Sample	25th Quartile	50th Quartile	75th Quartile	Conventional versus CE T1W	Interaction between Method and Threshold
PFS								
Pretreatment baseline/<15 cm ³ /160	0.58/.003	0.52/.001	Conventional/<15 cm ³ /90	2.9	6.9	15.3	.511	.701
			Conventional/≥15 cm ³ /70	2.8	2.1	7.2		
			CE T1W/<15 cm ³ /68	3.1	7.7	16.6		
			CE T1W/≥15 cm ³ /92	2.8	4.1	7.2		
Posttreatment follow-up (6 wk)/<7.5 cm ³ /131	0.51/.002	0.46/<.001	Conventional/<7.5 cm ³ /94	2.3	5.5	13.5	.624	.701
			Conventional/ ≥7.5 cm ³ /37	1.4	2.9	5.8		
			CE T1W/<7.5 cm ³ /82	2.7	7.2	13.5		
			CE T1W/≥7.5 cm ³ /49	1.4	2.7	5.5		
Percentage change in volume/≥25% (large) decrease/131	0.86/.598	0.46/.004	Conventional/≥25% (large) decrease/111	2.0	5.4	10.7	.025	.024
			Conventional/< 25% (small) decrease/20	1.3	5.5	13.5		
			CE T1W/≥25% (large) decrease/111	2.4	5.5	11.6		
			CE T1W/<25% (small) decrease/20	0.9	1.3	4.7		
OS								
Pretreatment baseline/<15 cm ³ /160	0.59/.002	0.50/.001	Conventional/<15 cm ³ /90	6.9	10.3	22.5	.41	.52
			Conventional/≥15 cm ³ /70	5.4	7.9	12.2		
			CE T1W/<15 cm ³ /68	8.0	13.1	24.1		
			CE T1W/≥15 cm ³ /92	5.1	7.9	11.9		

Measure/Threshold/ No. in Sample	Univariate Cox Model Hazard Ratio/ <i>P</i> Value		Survival Proportions (mo)*				<i>P</i> Value	
	Conventional	CE T1W	Method/Threshold/ No. in Sample	25th Quartile	50th Quartile	75th Quartile	Conventional versus CE T1W	Interaction between Method and Threshold
Posttreatment follow-up (6 wk)/<7.5 cm ³ /142	0.67/.041	0.46/<.001	Conventional/<7.5 cm ³ /100	5.0	9.2	17.8	.35	.17
			Conventional/≥7.5 cm ³ /42	4.8	7.8	10.5		
			CE T1W/<7.5 cm ³ /87	6.4	12.9	23.3		
			CE T1W/≥7.5 cm ³ /55	3.8	6.6	9.7		
Percentage change in volume/≥25% (large) decrease/142	0.78/.303	0.64/.053	Conventional/≥25% (large) decrease/116	5.4	9.1	15.0	.057	.051
			Conventional/<25% (small) decrease/26	3.8	7.4	25.9		
			CE T1W/≥25% (large) decrease/115	6.1	9.4	16.1		
			CE T1W/<25% (small) decrease/27	3.2	6.5	10.4		

Note.—Information from the BRAIN trial (study sponsor identification, AVF3708g; clinical trial registration no. NCT00345163). CE T1W = CE T1-weighted subtraction map method.

* The data for the 25th, 50th, and 75th quartiles refer to the time to the quartile (25th quartile, 75th quartile) and the median (50th quartile) survival from the population (eg, 25th quartile refers to 25th quartile of the population that did not have progression [PFS] or had not expired [OS]). Data in the 25th, 50th, and 75th quartile columns refer to the time it takes to reach this proportion of survival (eg, values in the 50th quartile column refer to median survival for that cohort of patients).